Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations
Gibbs Law Group reminds investors that a lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (“Amylyx Pharmaceuticals”) (NASDAQ: AMLX), on behalf of investors who purchased or acquired shares between November 11, 2022, and November 8, 2023.
- Gibbs Law Group reminds investors that a lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (“Amylyx Pharmaceuticals”) (NASDAQ: AMLX), on behalf of investors who purchased or acquired shares between November 11, 2022, and November 8, 2023.
- What Should Amylyx Pharmaceuticals Investors Do?
- Our investigation concerns whether Amylyx Pharmaceuticals has violated federal securities laws by providing false or misleading statements to investors.
- Following this announcement, Amylyx Pharmaceuticals shares plummeted over 81% in intraday trading on March 8, 2024, causing significant harm to investors.